ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02622386
Recruitment Status : Recruiting
First Posted : December 4, 2015
Last Update Posted : December 6, 2017
Sponsor:
Information provided by (Responsible Party):
Johann E Gudjonsson MD, PhD, University of Michigan

Brief Summary:
The purpose of this study is to determine the anti-inflammatory effect of high-dose riboflavin supplementation on chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms. Amongst patients with skin disease, there is significant interest in using complementary alternative medicine and vitamins to treat their disease. Previous human case reports suggest that riboflavin, commonly known as Vitamin B2, is clinically effective for the treatment of psoriasis; however, they were not conclusive. More recent human trials have shown that 400 mg of daily oral riboflavin is a safe and well-tolerated medication to administer to humans. For the purpose of this study, the riboflavin is used as an investigational drug.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Riboflavin Other: Placebo Phase 2

Detailed Description:
The purpose of this investigation is to determine the anti-inflammatory effect of high-dose riboflavin supplementation on chronic plaque psoriasis. Up to fifty volunteers with chronic plaque psoriasis will be recruited for a double-blind, placebo-controlled 28 week prospective study with cross-over of both the intervention and control groups at the 12 week time mark. There will be a 4 week washout period when subjects crossover. Riboflavin will be dosed 400 mg by mouth daily versus placebo. Throughout the study the investigators will perform both clinical and laboratory assessments to measure response.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis
Actual Study Start Date : August 11, 2016
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Riboflavin
Riboflavin (Vitamin B2) 400 mg oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive Riboflavin but matching placebo capsule for additional 12 weeks.
Drug: Riboflavin
Riboflavin (Vitamin B2) 400 mg capsule taken daily for 12 weeks.
Other Name: Vitamin B2
Placebo Comparator: Placebo
Placebo oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive placebo but 400 mg Riboflavin (Vitamin B2) capsule for additional 12 weeks.
Other: Placebo
Matching placebo capsule taken daily for 12 weeks.



Primary Outcome Measures :
  1. Subjects achieving 50% or greater psoriasis area and severity index (PASI) reduction [ Time Frame: 12 weeks ]
    The number of subjects that achieve a 50 percent or greater reduction in their PASI with intervention as compared to placebo.


Secondary Outcome Measures :
  1. Subjects achieving PASI 75, 90, 100 response [ Time Frame: 12 weeks ]
    The number of subjects that achieve a PASI 75, 90, 100 response with intervention as compared to placebo.

  2. Subjects achieving physician global assessment (PGA) score 0/1 [ Time Frame: 12 weeks ]
    The number of subjects that achieve a PGA score of 0/1 with intervention as compared to placebo.

  3. Subjects reporting pruritus score 0/1 [ Time Frame: 12 weeks ]
    The number of subjects that report a pruritus score of 0/1 with intervention as compared to placebo.

  4. Subjects reporting dermatology life quality index (DLQI) score 0/1 [ Time Frame: 12 weeks ]
    The number of subjects treated that report a DLQI score of 0/1 with intervention as compared to placebo.

  5. Difference in Riboflavin serum plasma levels and flavin-adenine dinucleotide (FAD) [ Time Frame: 12 weeks ]
    The difference in serum plasma levels of riboflavin and FAD in subjects treated with intervention as compared to placebo.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Good general health
  • Willingness and ability to follow the protocol
  • Signed Informed Consent Form, written and witnessed.
  • Stable moderate to severe chronic plaque psoriasis involving 8% or greater total body surface area (TBSA).
  • If subject is a woman of childbearing potential, she must have a negative pregnancy test at screening and agree to use a medically acceptable form of contraception during the screening and throughout the study.

Exclusion Criteria:

  • Started using a topical steroid stronger than moderate strength, vitamin A or D analog preparations, or anthralin within 14 days of study drug initiation.
  • Initiated a systemic medications, including biologic medication, or phototherapy within 180 days of study drug initiation.
  • Prior or concurrent use of cyclophosphamide.
  • Currently using sulfasalazine therapy.
  • Known hypersensitivity to riboflavin.
  • Enrolled in any other investigational device or investigational drug trial(s) or receipt of any other investigational agent(s) within 28 days of baseline visit.
  • Presence of severe comorbidities such as, diabetes mellitus requiring insulin; congestive heart failure (CHF) of any severity or myocardial infarction or cerebrovascular accident or transient ischemic attack within 3 months of screening visit; unstable angina pectoris, uncontrolled hypertension [sitting systolic BP <80 mm Hg or > 160 or diastolic BP > 100 mm Hg], oxygen-dependent severe pulmonary disease, history of cancer within 5 years [other than resected cutaneous basal or squamous cell carcinoma of the skin or in situ cervical cancer].
  • Any of the following hematologic abnormalities, confirmed by repeat test at least 1 week apart:

    1. White blood count <3,000/µL or >14,000/µL
    2. Lymphocyte count <1,000/µL
    3. Neutrophil count <1,5000/µL
    4. Platelet count <150,000/µL
    5. Hemoglobin<10 g/dL
  • Liver function test aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase (AlkP) results that are greater than or equal to 2 times the upper limit of normal (ULN).
  • Serum creatinine ≥ to 2x the ULN.
  • Known HIV-positive status or known history of any other immune-suppressing disease.
  • Any current or past history of psychiatric disease that would interfere with ability to comply with study protocol or give informed consent.
  • Had grade 3 or 4 adverse events or infections within 28 days before screening, or between screening visit and drug initiation.
  • Evidence of any skin conditions other than psoriasis that would interfere with the evaluations of the effect of study medication on psoriasis.
  • Presence of any condition or circumstances judged by the patient's physician, the investigator, or medically qualified study staff to render this clinical trial detrimental or otherwise unsuitable for the patient's participation.
  • A history of non-compliance with other therapies.
  • Females who are pregnant, lactating, planning on pregnancy during the study period, or unwilling to use FDA-approved method of birth control.
  • A history of keloids or excessive scar formation or of healing poorly.
  • A history of allergic reaction to local anesthetics, including lidocaine and epinephrine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02622386


Contacts
Contact: Jennifer Bell 734-936-4075 jennbell@med.umich.edu
Contact: Bethany Ruffino 734-763-8076 bruffino@med.umich.edu

Locations
United States, Michigan
University of Michigan Department of Dermatology Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Jennifer Bell    734-936-4075    jennbell@med.umich.edu   
Contact: Bethany Ruffino    734-763-8076    bruffino@med.umich.edu   
Sponsors and Collaborators
University of Michigan
Investigators
Principal Investigator: Johann Gudjonsson, MD University of Michigan

Responsible Party: Johann E Gudjonsson MD, PhD, Assistant Professor of Dermatology, University of Michigan
ClinicalTrials.gov Identifier: NCT02622386     History of Changes
Other Study ID Numbers: HUM00105691 /Derm 677
First Posted: December 4, 2015    Key Record Dates
Last Update Posted: December 6, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Johann E Gudjonsson MD, PhD, University of Michigan:
Psoriasis

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Vitamins
Riboflavin
Vitamin B Complex
Micronutrients
Growth Substances
Physiological Effects of Drugs
Photosensitizing Agents
Dermatologic Agents